Bernard Fermini

List of Publications by Year
in descending order

33	2,916	304743	454955
papers	citations	22 h-index	30 g-index

38	38	38	2137
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	On the perspective of an aging population and its potential impact on drug attrition and pre-clinical cardiovascular safety assessment. Journal of Pharmacological and Toxicological Methods, 2022, 117, 107184.	0.7	5
2	Use of automated patch clamp in cardiac safety assessment: past, present and future perspectives. Journal of Pharmacological and Toxicological Methods, 2021, 110, 107072.	0.7	20
3	Human Cardiac Ventricularâ€Like Organoid Chambers and Tissue Strips From Pluripotent Stem Cells as a Twoâ€Tiered Assay for Inotropic Responses. Clinical Pharmacology and Therapeutics, 2019, 106, 402-414.	4.7	36
4	Challenges in designing and executing clinical trials in a dish studies. Journal of Pharmacological and Toxicological Methods, 2018, 94, 73-82.	0.7	15
5	Clinical Trials in a Dish: A Perspective on the Coming Revolution in Drug Development. SLAS Discovery, 2018, 23, 765-776.	2.7	49
6	Proarrhythmia liability assessment and the comprehensive in vitro Proarrhythmia Assay (CiPA): An industry survey on current practice. Journal of Pharmacological and Toxicological Methods, 2017, 86, 34-43.	0.7	32
7	Measuring kinetics and potency of hERG block for CiPA. Journal of Pharmacological and Toxicological Methods, 2017, 87, 99-107.	0.7	41
8	Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative. Journal of Pharmacological and Toxicological Methods, 2017, 87, 11-23.	0.7	58
9	L-type calcium channel antagonism â€“ Translation from in vitro to in vivo. Journal of Pharmacological and Toxicological Methods, 2017, 84, 86-92.	0.7	10
10	Computational cardiology and risk stratification for sudden cardiac death: one of the grand challenges for cardiology in the 21st century. Journal of Physiology, 2016, 594, 6893-6908.	2.9	14
11	A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm. Journal of Biomolecular Screening, 2016, 21, 1-11.	2.6	259
12	Deranged sodium to sudden death. Journal of Physiology, 2015, 593, 1331-1345.	2.9	46
13	Use of an in vitro contractility assay to explore cardiac contractility changes observed in an in vivo cardiovascular study. Journal of Pharmacological and Toxicological Methods, 2013, 68, e21.	0.7	0
14	Comparative Gene Expression Profiling in Human-Induced Pluripotent Stem Cellâ€”Derived Cardiocytes and Human and Cynomolgus Heart Tissue. Toxicological Sciences, 2013, 131, 292-301.	3.1	41
15	Pharmacokineticâ€“pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys. Journal of Pharmacological and Toxicological Methods, 2011, 63, 304-313.	0.7	30
16	Species comparison of L-type Ca2+ currents in cardiac myocytes isolated from rat, rabbit, and non-human primate. Journal of Pharmacological and Toxicological Methods, 2011, 64, e5.	0.7	0
17	The use of alternate QRS measurement methods to improve detection of propafenone-induced QRS prolongation. Journal of Pharmacological and Toxicological Methods, 2011, 64, e39.	0.7	0
18	Recent Advances in Ion Channel Screening Technologies. Topics in Medicinal Chemistry, 2008, , 1-25.	0.8	8

#	Article	IF	Citations
19	Differentiation of Arrhythmia Risk of the Antibacterials Moxifloxacin, Erythromycin, and Telithromycin Based on Analysis of Monophasic Action Potential Duration Alternans and Cardiac Instability. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 352-359.	2.5	49
20	Evaluation of the Rubidium Efflux Assay for Preclinical Identification of hERG Blockade. Assay and Drug Development Technologies, 2006, 4, 73-82.	1.2	37
21	Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. European Journal of Pharmacology, 2004, 486, 209-221.	3.5	68
22	Pre-Clinical Assessment of Drug-Induced QT Interval Prolongation. Current Issues and Impact on Drug Discovery. Annual Reports in Medicinal Chemistry, 2004, 39, 323-334.	0.9	7
23	The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Reviews Drug Discovery, 2003, 2, 439-447.	46.4	444
24	Mechanism of Action Potential Prolongation by RP 58866 and Its Active Enantiomer, Terikalant. Circulation, 1996, 94, 2938-2946.	1.6	47
25	Adrenergic Modulation of Ultrarapid Delayed Rectifier K + Current in Human Atrial Myocytes. Circulation Research, 1996, 78, 903-915.	4.5	113
26	Use-Dependent Effects of the Class III Antiarrhythmic Agent NE-10064 (Azimilide) on Cardiac Repolarization. Journal of Cardiovascular Pharmacology, 1995, 26, 259-271.	1.9	116
27	Î±-Adrenergic Control of Volume-Regulated Cl â^' Currents in Rabbit Atrial Myocytes. Circulation Research, 1995, 77, 379-393.	4.5	79
28	Rapid and slow components of delayed rectifier current in human atrial myocytes. Cardiovascular Research, 1994, 28, 1540-1546.	3.8	218
29	Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents.. Circulation Research, 1993, 73, 1061-1076.	4.5	537
30	Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current.. Circulation Research, 1993, 73, 210-216.	4.5	309
31	Delayed rectifier outward current and repolarization in human atrial myocytes.. Circulation Research, 1993, 73, 276-285.	4.5	180
32	Amiodarone: Pharmacology, Clinical Actions, and Relationships Between Them. Journal of Cardiovascular Electrophysiology, 1992, 3, 266-280.	1.7	38
33	Sialic acid and the surface charge associated with hyperpolarization-activated, inward rectifying channels. Journal of Membrane Biology, 1990, 114, 61-69.	2.1	10